Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy With or Without Chemoembolization in Liver-Dominant Metastatic Colorectal Cancer
NCT00023868Phase 3Terminated
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Nov 2001
- Primary completion
- Sep 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, doxorubicin and mitomycin c in colorectal cancer (CRC) (2 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Overall Survival up to 5 years. Started Nov 2001; status: terminated.
02
Drugs
cisplatindoxorubicinmitomycin c
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00023868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023868.